Product Images Gabapentin

The text represents a Moan Pain Score with a value of 10. There is also mention of a dose titration period and a fixed dose period of 4 weeks. The interventions used were a placebo and Gabapentin, at a dose of 3600 mg per day. The text also includes an illustration of the weeks. It appears the text is a figure or chart from a study and is not sufficient to provide a full description.*

This appears to be a graph depicting the "Mean Pain Score" over a 4-week fixed dose period, with two different treatments being compared: "Gabapentin, 1800 mg/day" and "Gabapentin, 2400 mg/day." The baseline pain score is also shown.*

The text appears to be a figure showing the proportion of responders in controlled PHN studies which compares two different studies. The percentage of responders is shown as 10% and 100%, and there is additional data regarding the study participants' pain score, with a significant difference indicated by p-values. There also appears to be information regarding the cost of different treatments, with GBP amounts listed.*

This appears to be a formula for calculating creatinine clearance (CLCr), which is a measure of kidney function. The formula involves subtracting the patient's age in years from 140 and multiplying that number by their weight in kilograms, then multiplying their serum creatinine level in milligrams per deciliter by 72. The result is then adjusted by multiplying it by 0.85 for female patients.*

This appears to be a warning label for a medication called Gabapentin, which comes in 800 mg tablets and is packaged with 90 tablets per bottle. The manufacturer is Teva and the expiration date is not legible. The label also contains a product code (NDC:50436-7286-3) and a warning message stating "KON o 207 S".*